Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 3 8Phase 4 5Phase 1 5Phase NA 2Phase EARLY_PHASE1 2Phase 2/3 2Phase 1/2 2

Status

Completed 6Withdrawn 2Terminated 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 6pembrolizumab 5Radiosurgery 5Nivolumab 4Fluorouracil 4Carboplatin 4Blood Specimen Collection 4Biopsy 4X-Rays 3Vincristine 3Surveys and Questionnaires 3Proflavine 3Positron-Emission Tomography 3Metformin 3Cisplatin 3Bevacizumab 3fludarabine phosphate 2durvalumab 2atezolizumab 2Varenicline 2Topotecan 2Taxes 2Specimen Handling 2Rituximab 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Oxaliplatin 2Leucovorin 2Letrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Terminated × Letrozole × Clear all
NCT04102618 2022-08-15

AWARE-1

Oncolytics Biotech

Phase EARLY_PHASE1 Terminated
26 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00651976 2018-10-15

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Terminated
213 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡